Evidence map›Paper›PMID 42719362›Full record

ArticleActa histochemica et cytochemica2026

Heterogeneous Expression of TREM2 And STAB1 Among Tumor-Associated Macrophages in Clear-Cell Renal Cell Carcinoma.

Ren Shirotani, Tomoka Takahashi, Jie Su, Ayano Uekawa, Yojiro Ozaki, Yuki Ibe, Cheng Pan, Daiki Yoshii, Yukio Fujiwara, Toshiki Anami and 6 more

Abstract read
In one paragraph

Article in Acta histochemica et cytochemica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ren ShirotaniDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Tomoka TakahashiDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Jie SuDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Ayano UekawaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yojiro OzakiDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yuki IbeDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Cheng PanDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Daiki YoshiiDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yukio FujiwaraDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Toshiki AnamiDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Hidekazu NishizawaDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Ryoma KurahashiDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yoji MurakamiDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Junji YatsudaDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Tomomi KambaDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yoshihiro KomoharaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) play important roles in shaping the tumor microenvironment and regulating antitumor immune responses. Triggering receptor expressed on myeloid cells 2 (TREM2) and stabilin-1 (STAB1/CLEVER1) have recently attracted attention as molecules associated with immunosuppressive macrophage phenotypes; however, their expression patterns in clear-cell renal cell carcinoma (ccRCC) remain unclear. This study aimed to examine TREM2 and STAB1 expression in ccRCC using public transcriptomic datasets and public single-cell RNA sequencing data, as well as immunohistochemistry using ccRCC specimens. In the TCGA cohort, high TREM2 and STAB1 mRNA expression was associated with poor overall survival and advanced tumor stage. In an independent immunohistochemistry cohort, TREM2 was expressed mainly in TAMs, whereas STAB1 was expressed in both TAMs and endothelial cells. TREM2-positive TAM density was significantly associated with high nuclear grade, whereas STAB1-positive TAM density was not. Double immunohistochemistry and single-cell RNA sequencing analyses suggested different, but partially overlapping, expression patterns of TREM2 and STAB1 among TAMs. TREM2-high TAMs showed features of monocyte-derived macrophages, whereas STAB1-high TAMs showed features associated with tissue-resident macrophages. These findings suggest that TREM2-positive TAMs and STAB1-positive TAMs contribute differently to the immune microenvironment of ccRCC. Further studies are needed to clarify their functional significance and therapeutic potential.

Indexed as

CD163CD204CLEVER1STAB1TREM2

Identifiers

PMID42719362
PMCPMC13554459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.